Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Our key focus therapeutic areas are: • Endocrinology • Dermatology • Anaesthesia and analgesia • Ophthalmology • Cardiovascular disease • Equine locomotion • Food producing animal antimicrobials • And pet diets
Lostock Gralam, GB
Size (employees)
1,338 (est)+3%
Dechra Pharmaceuticals was founded in 1997 and is headquartered in Lostock Gralam, GB
Report incorrect company information

Dechra Pharmaceuticals Office Locations

Dechra Pharmaceuticals has offices in Lostock Gralam, Hadnall, Skipton, Melbourne and in 6 other locations
Lostock Gralam, GB (HQ)
Cheshire Business Park Roundabout
Hadnall, GB
Sansaw Business Park Hardwicke Stables
Skipton, GB
Snaygill Industrial Estate Keighley Rd
Uldum, DK
9 Mekuvej
Torino, IT
Via Agostino da Montefeltro
Barcelona, ES
202 Carrer de Balmes
Show all (10)
Report incorrect company information

Dechra Pharmaceuticals Financials and Metrics

Dechra Pharmaceuticals Financials

Dechra Pharmaceuticals's revenue was reported to be £247.56 m in FY, 2016 which is a 21.7% increase from the previous period.

Revenue (FY, 2016)

247.6 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

132.4 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

12.5 m

Market capitalization (31-Oct-2017)

1.9 b

Closing share price (31-Oct-2017)


Cash (30-Jun-2016)

39.1 m
Dechra Pharmaceuticals's current market capitalization is £1.9 b.
GBPFY, 2013FY, 2014FY, 2015FY, 2016


189.2 m193.6 m203.5 m247.6 m

Revenue growth, %


Cost of goods sold

88.5 m85.9 m87.3 m115.1 m

Gross profit

100.7 m107.7 m116.1 m132.4 m
GBPFY, 2014FY, 2015FY, 2016


26.8 m45.9 m39.1 m

Accounts Receivable

28.3 m27.7 m59.2 m

Current Assets

86.3 m108.6 m162.5 m


18.3 m18.2 m37.9 m
GBPFY, 2014FY, 2015FY, 2016

Cash From Operating Activities

11.5 m41 m43.6 m

Cash From Financing Activities

(92.1 m)(14.8 m)125.3 m

Income Taxes Paid

(2 m)(6.3 m)(2 m)
GBPY, 2016


286.9 k

Financial Leverage

2 x
Show all financial metrics
Report incorrect company information

Dechra Pharmaceuticals News and Updates

Pet Oral Care Market by Key Manufacturers (Allaccem, Inc., Ceva Sante Animale S.A., Colgate-Palmolive Company, Dechra Pharmaceuticals Plc. ) Forecast to 2025 has announced the addition of the “Global Pet Oral Care Market Size Status and Forecast 2025” The report detailed insights about the aspects responsible for augmenting as well as restraining market growth. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information